Research Progress of Anti-lung Cancer Drug-related Interstitial Lung Disease.
10.3779/j.issn.1009-3419.2025.106.11
- Author:
Zhimin XIAO
1
;
Yan GU
1
Author Information
1. Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Inner Mongolia Medical University,
Hohhot 010107, China.
- Publication Type:English Abstract
- Keywords:
Anti-lung cancer drugs;
Drug-induced interstitial lung disease;
Immune checkpoint inhibitors;
Lung neoplasms;
Multidisciplinary collaboration;
Tyrosine kinase inhibitors
- MeSH:
Humans;
Lung Diseases, Interstitial/therapy*;
Lung Neoplasms/drug therapy*;
Antineoplastic Agents/therapeutic use*
- From:
Chinese Journal of Lung Cancer
2025;28(4):309-318
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is the cancer with the highest incidence and mortality rate worldwide. In addition to the diversified treatment and prolonged lifespan in view of the development of medical technology, the side effect of medicine should not be ignored. Drug-induced interstitial lung disease (DI-ILD) is also commonly encountered during this process, and ILD triggered by the treatment of lung cancer characterized by the inflammation and scarring of lung tissue after the antitumor treatment in lung cancer leads to a poor prognosis and high mortality. The diagnosis and treatment of ILD caused by anti-lung cancer agents remains challenging in clinical settings and requires joint efforts from multidisciplinary team (MDT). This review systematically updates the epidemiology, molecular pathogenesis, genomics/genetics study, diagnosis and treatment of ILD related to anti-lung cancer agents. By the integration of the latest evidences, the paper offers clinical work references for early diagnosis of ILD related to anti-lung cancer agents to enhance the survival and quality of life of the lung cancer patients.
.
